EFS | OS | |||
---|---|---|---|---|
HR (95% CI) | p value | HR (95% CI) | p value | |
All patients | ||||
Unadjusted | 1.22 (0.96–1.56) | 0.10 | 1.29 (0.99–1.68) | 0.055 |
Adjusted for local treatmenta | 1.14 (0.87–1.51) | 0.34 | 1.25 (0.93–1.68) | 0.15 |
Adjusted for between the start of chemotherapy and starting local treatment | 1.13 (0.88–1.45) | 0.34 | 1.19 (0.91–1.56) | 0.20 |
Adjusted for both local treatment and timing | 1.11 (0.84–1.47) | 0.46 | 1.21 (0.90–1.65) | 0.21 |
Localised disease only | ||||
Unadjusted | 1.31 (0.97–1.76) | 0.08 | 1.39 (1.00–1.93) | 0.048 |
Adjusted for local treatmenta | 1.22 (0.87–1.72) | 0.25 | 1.30 (0.89–1.90) | 0.17 |
Adjusted for between the start of chemotherapy and starting local treatment | 1.18 (0.87–1.60) | 0.30 | 1.24 (0.88–1.74) | 0.21 |
Adjusted for local treatment and the time between the start of chemotherapy and starting local treatment | 1.14 (0.81–1.62) | 0.45 | 1.20 (0.82–1.77) | 0.35 |
Metastatic disease only | ||||
Unadjusted | 0.98 (0.65–1.48) | 0.93 | 1.01 (0.66–1.57) | 0.94 |
Adjusted for local treatmenta | 0.98 (0.61–1.56) | 0.93 | 1.11 (0.68–1.81) | 0.69 |
Adjusted for between the start of chemotherapy and starting local treatment | 0.95 (0.62–1.45) | 0.81 | 1.00 (0.64–1.57) | 0.98 |
Adjusted for both local treatment and timing | 0.99 (0.61–1.60) | 0.97 | 1.14 (0.69–1.89) | 0.60 |